CYTO NK-201 / CytoImmune - LARVOL DELTA

CytoImmune Presents New Preclinical Data Demonstrating Potential of its Novel, Off-the-Shelf Natural Killer Cell-Based Therapies for the Treatment of Hematologic and Solid Tumor Cancers at AACR (Businesswire) - "CytoImmune Therapeutics...announced new preclinical data supporting the therapeutic potential of its CYTO-102 and CYTO-201 programs as treatments for patients with cancer....The data are being presented at the American Association for Cancer Research (AACR) Annual Meeting....Significant cytotoxicity against a human NSCLC cell line when compared to NK cells without expression of sIL-15, NK cells without expression PD-L1, or NK cells without expression of both....Reduced tumor burden and prolonged survival in an aggressive AML mouse model when compared to cells only expressing IL-15 or to the control group."

Preclinical • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Thoracic Cancer

City of Hope to Present Late-Breaking and Clinical Trial Data at AACR: Cell Therapy and Preventive Medicine (Businesswire) - "Researchers at City of Hope...will present late-breaking and clinical trial findings at this year’s American Association for Cancer Research Annual Meeting....Jianhua Yu, Michael Caligiuri and colleagues have developed a new cell therapy approach using natural killer cells that, in lab models, induced a greater response against acute myeloid leukemia (AML) and lengthened the survival of mice with AML without damaging healthy blood stem cells....When tested in mice transplanted with human non-small cell lung cancer, the innovative cell therapy City of Hope developed worked better than un-engineered natural killer cells and did not appear to affect body weight, liver or kidney function, or blood counts....The research team treated mice with brain tumors first with the oncolytic virus, then with cell therapy, and showed that together the two treatments did not cause any side effects."

Late-breaking abstract • Preclinical • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology

CytoImmune to Present New Preclinical Data Highlighting Potential of Novel TRACK-NK Cell Therapies as Treatments for both Solid Tumors and Hematologic Malignancies (Businesswire) - "CytoImmune Therapeutics...announced that the company will present preclinical data from its FLT3 CAR-NK cell program for acute myeloid leukemia and its TRACK-NK™ program for non-small cell lung cancer at the American Association for Cancer Research (AACR) Annual Meeting....Data to be presented during late breaker poster sessions at 2022 AACR Annual Meeting."

Late-breaking abstract • Preclinical • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor